VenoVision
Non-invasive, easy-to-use advanced cardiac and hemodynamic monitoring.
Company Overview
Snapshot
Founded in September 2022 by Nadav Lankin, Dr. Tal Hasin, Prof. Yaakov Nahmias, and Jonathan Maron, VenoVision operates with 1–10 employees. The company has raised $187.5K across 5 funding rounds and holds a patent for its technology. In September 2022, VenoVision was selected for the Health Wildcatters 2022 Program in Texas, aiming to enhance patient monitoring.
Business overview
VenoVision specializes in advanced cardiac and hemodynamic monitoring, providing non-invasive, easy-to-use solutions for heart failure and at-risk patients. The company's core technology utilizes thermal imaging to deliver ICU-level hemodynamic data in diverse settings, from inpatient to home care, specifically addressing challenges in monitoring obese patients. VenoVision operates within the Health Tech & Life Sciences sector, focusing on digital healthcare and medical devices to reduce preventable deterioration and rehospitalizations.
Strategic signal
VenoVision's selection for the Health Wildcatters 2022 Program in September 2022 highlights its potential for market validation and strategic growth within the health tech ecosystem. This accelerator participation signals to investors a commitment to refining its technology and business model, leveraging mentorship and resources to advance its non-invasive cardiac monitoring solution. It suggests a focus on market integration and scaling its impact on patient care.
Company Intelligence Q&A
- What is VenoVision's primary focus?
- VenoVision focuses on providing non-invasive, easy-to-use advanced cardiac and hemodynamic monitoring to improve the lives of heart failure and at-risk patients.
- When was VenoVision founded and by whom?
- VenoVision was founded in September 2022 by Nadav Lankin, Dr. Tal Hasin, Prof. Yaakov Nahmias, and Jonathan Maron.
- What significant program was VenoVision selected for in 2022?
- In September 2022, VenoVision was selected for the Health Wildcatters 2022 Program in Texas, aimed at improving patient monitoring.
- What is VenoVision's total capital raised?
- VenoVision has raised a total of $187.5K across 5 funding rounds.
- What is VenoVision's core technology?
- VenoVision's core technology involves a low-cost, easy-to-use, thermal imaging-based hemodynamic monitoring device and platform designed for various care settings.